Literature DB >> 25028066

Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study.

Arsène Mekinian1, Nathalie Costedoat-Chalumeau, Agathe Masseau, Angela Botta, Anastasia Chudzinski, Arnaud Theulin, Virginie Emmanuelli, Eric Hachulla, Sara De Carolis, Aurélie Revaux, Pascale Nicaise, Françoise Cornelis, Damien Subtil, Francois Montestruc, Martine Bucourt, Sylvie Chollet-Martin, Lionel Carbillon, Olivier Fain.   

Abstract

UNLABELLED: Introduction: In this prospective multicenter study, we aimed to describe (1) the outcome of pregnancy in the case of previous chronic histiocytic intervillositis (CHI), (2) the immunological findings and associated diseases, (3) the treatments, and (4) the factors associated with pregnancy loss.
METHODS: We prospectively included all patients with a prior CHI with ongoing pregnancy between 2011 and 2013.
RESULTS: Twenty-four women (age 34±5 years) were included in this study. An autoimmune disease was present in seven (29%) cases. Twenty-one prospective pregnancies were treated. The number of live births was more frequent comparatively to the previous obstetrical issues (16/24 versus 24/76; p=0.003). Most of the pregnancies were treated (88%), whereas only 13% of previous pregnancies were treated (p<0.05). No difference was found with respect to the pregnancy outcome in the different treatment regimens. In univariate analyses, a prior history of intrauterine death and intrauterine growth restriction and the presence of CHI in prospective placentas were associated with failure to have a live birth. DISCUSSION: In this multicenter study, we show the frequency of the associated autoimmune diseases in CHI, as well as the presence of autoantibodies without characterized autoimmune disease. The number of live births increased from 32% to 67% in the treated pregnancies. Despite the treatment intervention, the risk of preterm delivery remained at 30%. Last, we show that the recurrence rate of an adverse pregnancy outcome persisted at 30% despite treatment intervention.
CONCLUSION: CHI is associated with high recurrence rate and the combined regimen seems to be necessary, in particular, in the presence of previous intrauterine death.

Entities:  

Keywords:  Autoimmune disease; chronic histiocytic intervillositis; outcome; treatment

Mesh:

Substances:

Year:  2014        PMID: 25028066     DOI: 10.3109/08916934.2014.939267

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  7 in total

1.  FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction.

Authors:  Nir Melamed; Ahmet Baschat; Yoav Yinon; Apostolos Athanasiadis; Federico Mecacci; Francesc Figueras; Vincenzo Berghella; Amala Nazareth; Muna Tahlak; H David McIntyre; Fabrício Da Silva Costa; Anne B Kihara; Eran Hadar; Fionnuala McAuliffe; Mark Hanson; Ronald C Ma; Rachel Gooden; Eyal Sheiner; Anil Kapur; Hema Divakar; Diogo Ayres-de-Campos; Liran Hiersch; Liona C Poon; John Kingdom; Roberto Romero; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-03       Impact factor: 3.561

2.  One-Sided Chronic Intervillositis of Unknown Etiology in Dizygotic Twins: A Description of 3 Cases.

Authors:  Lotte E van der Meeren; Juliette Krop; Kyra L Dijkstra; Kitty W M Bloemenkamp; Emily F Cornish; Peter G J Nikkels; Marie-Louise P van der Hoorn; Manon Bos
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 3.  Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome.

Authors:  Emily F Cornish; Thomas McDonnell; David J Williams
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 4.  Maternal-Fetal Inflammation in the Placenta and the Developmental Origins of Health and Disease.

Authors:  Jeffery A Goldstein; Kelly Gallagher; Celeste Beck; Rajesh Kumar; Alison D Gernand
Journal:  Front Immunol       Date:  2020-11-13       Impact factor: 7.561

5.  Chronic histiocytic intervillositis (CHI): current treatments and perinatal outcomes, a systematic review and a meta-analysis.

Authors:  Laurel Moar; Chloe Simela; Surabhi Nanda; Andreas Marnerides; Mudher Al-Adnani; Catherine Nelson-Piercy; Kypros H Nicolaides; Panicos Shangaris
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

6.  Placenta histopathology in SARS-CoV-2 infection: analysis of a consecutive series and comparison with control cohorts.

Authors:  Luca Bertero; Fulvio Borella; Paola Cassoni; Chiara Benedetto; Giovanni Botta; Andrea Carosso; Stefano Cosma; Marialuisa Bovetti; Marco Carosso; Giancarlo Abbona; Giammarco Collemi; Mauro Papotti
Journal:  Virchows Arch       Date:  2021-05-01       Impact factor: 4.064

Review 7.  The Potential Benefit of Hydroxychloroquine in Chronic Placental Inflammation of Unknown Etiology Associated with Adverse Pregnancy Outcomes.

Authors:  Alexandra Bouariu; Nicolae Gică; Anca Marina Ciobanu; Ana Maria Scutelnicu; Mihaela Roxana Popescu; Anca Maria Panaitescu
Journal:  Healthcare (Basel)       Date:  2022-01-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.